Literature DB >> 10903780

CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness.

M Dybul1, G Mercier, M Belson, C W Hallahan, S Liu, C Perry, B Herpin, L Ehler, R T Davey, J A Metcalf, J M Mican, R A Seder, A S Fauci.   

Abstract

It has been suggested that CD4+ T cell proliferative responses to HIV p24 Ag may be important in the control of HIV infection. However, these responses are minimal or absent in many HIV-infected individuals. Furthermore, while in vitro and in vivo responses to non-HIV recall Ags improve upon administration of highly active antiretroviral therapy, there does not appear to be a commensurate enhancement of HIV-specific immune responses. It is possible that CD4+ p24-specific T cells are deleted early in the course of infection. However, it is also possible that a discrete unresponsiveness, or anergy, contributes to the lack of proliferation to p24. To evaluate the possible contribution of unresponsiveness to the lack of CD4+ T cell proliferation to p24 in HIV-infected individuals, we attempted to overcome unresponsiveness. CD40 ligand trimer (CD40LT) and IL-12 significantly increased PBMC and CD4+ T cell proliferative responses to p24 Ag in HIV-infected, but not uninfected, individuals. No increase in proliferative response to CMV Ag was observed. CD40LT exerted its effect through B7-CD28-dependent and IL-12- and IL-15-independent mechanisms. Finally, the increase in proliferation with CD40LT and IL-12 was associated with an augmented production of IFN-gamma in most, but not all, individuals. These data suggest the possible contribution of HIV-specific unresponsiveness to the lack of CD4+ T cell proliferation to p24 Ag in HIV-infected individuals and that clonal deletion alone does not explain this phenomenon. They also indicate the potential for CD40LT and IL-12 as immune-based therapies for HIV infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903780     DOI: 10.4049/jimmunol.165.3.1685

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Highly active antiretroviral therapy in patients infected with human immunodeficiency virus increases CD40 ligand expression and IL-12 production in cells ex vivo.

Authors:  Alice M Nyakeriga; Jun Ying; Norah J Shire; Carl J Fichtenbaum; Claire A Chougnet
Journal:  Viral Immunol       Date:  2011-08       Impact factor: 2.257

2.  Mucosal and systemic antibody responses in humans infected with simian foamy virus.

Authors:  James E Cummins; Roumiana S Boneva; William M Switzer; Logan L Christensen; Paul Sandstrom; Walid Heneine; Louisa E Chapman; Charlene S Dezzutti
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.

Authors:  M Dybul; T W Chun; C Yoder; B Hidalgo; M Belson; K Hertogs; B Larder; R L Dewar; C H Fox; C W Hallahan; J S Justement; S A Migueles; J A Metcalf; R T Davey; M Daucher; P Pandya; M Baseler; D J Ward; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

4.  Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques.

Authors:  A A Ansari; A E Mayne; J B Sundstrom; P Bostik; B Grimm; J D Altman; F Villinger
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  The Role of CD4(+) and CD8(+) T Cells in Controlling HIV Infection.

Authors:  Stephen A. Migueles; Mark Connors
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

6.  Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway.

Authors:  Elizabeth A Miller; Meredith R Spadaccia; Meagan P OʼBrien; Linda Rolnitzky; Rachel Sabado; Olivier Manches; Davor Frleta; Nina Bhardwaj
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-15       Impact factor: 3.731

7.  Disruption of MAP kinase activation and nuclear factor binding to the IL-12 p40 promoter in HIV-infected myeloid cells.

Authors:  K A Chambers; R J Parks; J B Angel
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 8.  Dendritic cell dysregulation during HIV-1 infection.

Authors:  Elizabeth Miller; Nina Bhardwaj
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

9.  Immunity to human immunodeficiency virus (HIV) in children with chronic HIV infection receiving highly active antiretroviral therapy.

Authors:  Adriana Weinberg; Gregory B Pott
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

10.  CD4 responses to conserved HIV-1 T helper epitopes show both negative and positive associations with virus load in chronically infected subjects.

Authors:  M J Boaz; A Waters; S Murad; P J Easterbrook; E D'Sousa; C van Wheeley; A Vyakarnam
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.